期刊文献+

血清NSE、TPS、Ang-2与NSCLC患者TNM分期的相关性研究 被引量:2

Correlation between serum NSE, TPS, Ang-2 and TNM staging in patients with NSCLC
下载PDF
导出
摘要 目的研究血清神经元特异性烯醇化酶(neuron specific enolase,NSE)、组织多肽特异性抗原(tissue polypeptide specific antigen,TPS)、血管生成素-2(Angiopoietin-2,Ang-2)与非小细胞肺癌(non-small cell lung cancer,NSCLC)患者TNM分期的相关性。方法将本院自2016年1月~2018年12月收治的149例NSCLC患者纳入NSCLC组,另将同期于本院接受健康体检的30例健康志愿者纳入对照组。比较两组血清NSE、TPS、Ang-2水平,绘制受试者工作特征(Receiver Operating Characteristic,ROC)曲线分析血清NSE、TPS、Ang-2对NSCLC的诊断价值;并比较不同TNM分期的NSCLC患者血清NSE、TPS、Ang-2水平,Spearman相关性分析法分析血清NSE、TPS、Ang-2与TNM分期的相关性。结果NSCLC组血清NSE、TPS、Ang-2均显著高于对照组(P<0.05);单一指标诊断时TPS诊断效能最佳,敏感度、特异度为84.30%、93.33%;NSE、TPS、Ang-2联合诊断时敏感度、特异度为90.60%、93.30%;同时,NSCLC患者血清NSE、TPS、Ang-2随TNM增加而上升,差异有统计学意义(P<0.05),且血清NSE、TPS、Ang-2与TNM分期显著正相关(r=0.230、0.574、0.344,均P<0.01)。结论NSCLC患者血清NSE、TPS、Ang-2存在异常高表达现象,联合应用可对NSCLC发挥优势诊断效能,且其水平随TNM分期增加而上升,与TNM分期显著正相关,值得临床重视。 Objective To study the correlation between serum neuron specific enolase(NSE),tissue polypeptide specific antigen(TPS),angiopoietin-2(Ang-2)and TNM staging in patients with non-small cell lung cancer(NSCLC).Methods A total of 149 patients with NSCLC from January 2016 to December 2018 were included in the NSCLC group.Another 30 healthy volunteers who received a physical examination at the same time were included in the control group.The levels of serum NSE,TPS and Ang-2 were compared between the two groups.The receiver operating characteristic(ROC)curve was used to analyze the diagnostic value of serum NSE,TPS and Ang-2 on NSCLC.The levels of serum NSE,TPS and Ang-2 were compared among NSCLC patients with different TNM stages,and Spearman correlation analysis was used to analyze the correlation between serum NSE,TPS,Ang-2 and TNM staging.Results The levels of serum NSE,TPS and Ang-2 in the NSCLC group were significantly higher than those in the control group(P<0.05).TPS had the best diagnostic efficiency when single index was diagnosed,with the sensitivity and specificity of 84.30%and 93.33%.The sensitivity and specificity of NSE,TPS and ang-2 were 90.60%and 93.30%respectively.The levels of serum NSE,TPS and Ang-2 of NSCLC patients increased with the increase of TNM(P<0.05),and serum NSE,TPS and Ang-2 were significantly positively correlated with TNM staging(r=0.230,0.574,0.344,all P<0.01).Conclusion The serum NSE,TPS and Ang-2 are abnormally highly expressed in NSCLC patients,and the combined application can play an advantageous role in the diagnosis of NSCLC,and its level increases with the increase of TNM stage,which is significantly positively correlated with TNM stage,and is worthy of clinical attention.
作者 陈燕 许立新 李美 李凌 曹晓芸 CHEN Yan;XU Li-xin;LI Mei;LI Ling;CAO Xiao-yun(Department of Clinical laboratory,Jiangbei District of the Affiliated Zhongda Hospital of Southeast University,Nanjing,Jiangsu 210044,China;Nanjing Luhe People s Hospital,Nanjing,Jiangsu 211500,China)
出处 《临床肺科杂志》 2019年第12期2240-2244,共5页 Journal of Clinical Pulmonary Medicine
关键词 神经元特异性烯醇化酶 组织多肽特异性抗原 血管生成素-2 非小细胞肺癌 TNM分期 neuron specific enolase tissue polypeptide specific antigen angiopoietin-2 non-small cell lung cancer TNM staging
  • 相关文献

参考文献8

二级参考文献83

  • 1Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin, 2011, 61(2): 69-90.
  • 2郝捷,陈万青.2012中国肿瘤登记年报.第1版.北京:军事医学科学出版社,2012,1-301.
  • 3Petrelli NJ, Winer EP, Brahmer J, et al. Clinical Cancer Advances 2009: major research advances in cancer treatment, prevention, and screening- a report from the American Society of Clinical Oncology. J Clin Oncol, 2009, 27(35): 6052-6069.
  • 4Pimentel FL, Bhalla S, Laranjeira L, et al. Cost-minimization analysis for Portugal of five doublet chemotherapy regimens from two phaseⅢ trials in the treatment of advanced non-smaU cell lung cancer. Lung Cancer, 2006, 52(3): 365-371.
  • 5Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phaseⅢ trial. Lancet, 2008, 372(9652): 1809-1818.
  • 6Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med, 2009, 361 (10): 947-957.
  • 7Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previouslytreated non-small-cell lung cancer. N EnglJ Med, 2005, 353(2): 123-132.
  • 8Tiseo M, Gridelli C, Cascinu S, et al. An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): data report from Italy. Lung Cancer, 2009, 64(2): 199-206.
  • 9Ciuleanu T, Stelmakh L, Cicenas S, et al. Efficacy and safety of erlotinib ver- sus chemotherapy in second-line treatment of patients with advanced, non- small-cell lung cancer with poor prognosis (TITAN): a randomised muiti- centre, open-label, phase 3 study. Lancet Oncol, 2012, 13(3): 300-308.
  • 10Florescu M, Hasan B, Seymour L, et al. A clinical prognostic index for pa- tients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group study BR.21.J Tnorac Oncol, 2008, 3(6): 590-598.

共引文献236

同被引文献30

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部